NORTH BRUNSWICK, N.J., Feb. 12 /PRNewswire/ -- WellGen, Inc., a biotechnology company using nutrigenomics to discover and develop food ingredients for wellness products, today announced the appointment of Robert M. Hellauer as Chief Financial Officer.
Mr. Hellauer, 56, comes to WellGen with over thirty years of broad financial leadership in the pharmaceutical, consumer and telecommunications industries. Prior to joining WellGen, he spent six years in private equity and venture-backed environments. Mr. Hellauer's earlier experience includes senior positions at Lucent Technologies / AT&T, General Signal Corporation, and Johnson & Johnson.
Dr. Kathleen Mullinix, Chief Executive Officer of WellGen, said, "Bob joins WellGen at a strategically important period, as we emerge from our origins as a research boutique and gain traction as a commercial entity. The role of Chief Financial Officer will be critical to ensuring a successful, sustainable business as we roll out our first functional food ingredient to the marketplace and significantly expand the number of ingredients in our pipeline."
Mr. Hellauer graduated from the University of Pennsylvania, where he received a Bachelor of Science degree and a Master of Business Administration degree from The Wharton School.
WellGen, Inc., based in North Brunswick, NJ, is a biotechnology company that is discovering and developing products for the food, therapeutics, and dietary supplement markets, with a strategic focus on functional foods. WellGen's proprietary technology platform is a method of screening the effects of food and related substances on the expression of genes associated with human health conditions. The company has developed proprietary substances that help maintain health and reduce risk and severity for a variety of diseases. Please visit our website at http://www.wellgen.com for more information.